alendronate has been researched along with Esophageal Neoplasms in 8 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Controversy still exists regarding whether alendronate (ALN) use increases the risk of esophageal cancer or breast cancer." | 7.78 | A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. ( Chang, SN; Kao, CH; Lee, WY; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2012) |
| "Controversy still exists regarding whether alendronate (ALN) use increases the risk of esophageal cancer or breast cancer." | 3.78 | A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. ( Chang, SN; Kao, CH; Lee, WY; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2012) |
| "Alendronate users had a lower risk of incident gastric cancer [odds ratio (OR) 0." | 1.38 | Esophageal and gastric cancer incidence and mortality in alendronate users. ( Abrahamsen, B; Eastell, R; Eiken, P; Pazianas, M; Russell, RG, 2012) |
| "The odds of being a case of oesophageal cancer, adjusted for smoking status, were significantly increased in women who had had one or more bisphosphonate prescriptions, odds ratio 1." | 1.38 | Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD). ( Molokhia, M; Schofield, PT; Seed, P; Wright, E, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wright, E | 2 |
| Schofield, PT | 2 |
| Molokhia, M | 2 |
| Wysowski, DK | 1 |
| Shaheen, NJ | 1 |
| Abrahamsen, B | 1 |
| Pazianas, M | 1 |
| Eiken, P | 1 |
| Russell, RG | 1 |
| Eastell, R | 1 |
| Chen, YM | 1 |
| Chen, DY | 1 |
| Chen, LK | 2 |
| Tsai, YW | 1 |
| Chang, LC | 1 |
| Huang, WF | 1 |
| Liu, CL | 1 |
| Chen, YT | 1 |
| Hsiao, FY | 1 |
| Seed, P | 1 |
| Lee, WY | 1 |
| Sun, LM | 1 |
| Lin, MC | 1 |
| Liang, JA | 1 |
| Chang, SN | 1 |
| Sung, FC | 1 |
| Muo, CH | 1 |
| Kao, CH | 1 |
| Terashima, T | 1 |
| Hiramatsu, K | 1 |
| Shimatani, A | 1 |
| Matsuda, M | 1 |
| Ogino, H | 1 |
| Satomura, Y | 1 |
| Noda, Y | 1 |
1 review available for alendronate and Esophageal Neoplasms
| Article | Year |
|---|---|
Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Esophageal Neoplasms; Humans; Stomach | 2015 |
7 other studies available for alendronate and Esophageal Neoplasms
| Article | Year |
|---|---|
Reports of esophageal cancer with oral bisphosphonate use.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Esophagea | 2009 |
More on reports of esophageal cancer with oral bisphosphonate use.
Topics: Alendronate; Bone Density Conservation Agents; Control Groups; Diphosphonates; Esophageal Neoplasms; | 2009 |
Esophageal and gastric cancer incidence and mortality in alendronate users.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Denmark; Esophageal Neoplasms; Etidronic | 2012 |
Alendronate and risk of esophageal cancer: a nationwide population-based study in Taiwan.
Topics: Alendronate; Bone Density Conservation Agents; Case-Control Studies; Esophageal Neoplasms; Humans; R | 2011 |
Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Databases, Factual; Dipho | 2012 |
A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Coh | 2012 |
An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Esophageal Diseases; Esophag | 2006 |